Advertisement

Ovarian Cancer pp 183-195 | Cite as

Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients

  • Mandi M. Murph
  • Debra L. Smith
  • Bryan Hennessy
  • Yiling Lu
  • Corwin Joy
  • Kevin R. Coombes
  • Gordon B. Mills
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

In 1970s, President Nixon declared a war on cancer and signed the National Cancer Act with an expectation of finding a cure. For at least a subset of cancers such as childhood leukemias, we have made remarkable progress to the point where survival is an expectation rather than a rarity. Although we do not have one panacea for all human cancers, 30 years later, we understand that each type of cancer and potentially each person’s cancer is different, and it will take the development of rationale combination therapies to cure all cancers. To reach Nixon’s idealistic goal, medical oncology care will need to become individualized. Specifically targeted drugs continue to receive FDA approval and guide treatment selection on the basis of the underlying dysfunctional genetic, transcriptional, or protein regulation driving their tumor progression.

Keywords

Acute Myelogenous Leukemia PI3K Pathway Cutaneous Leishmaniasis Reverse Phase Protein Array Farnesyltransferase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer 2008

Authors and Affiliations

  • Mandi M. Murph
  • Debra L. Smith
  • Bryan Hennessy
  • Yiling Lu
  • Corwin Joy
  • Kevin R. Coombes
  • Gordon B. Mills

There are no affiliations available

Personalised recommendations